(MENAFN- GetNews) The Key Congenital Adrenal Hyperplasia Companies in the market include - Neurocrine Biosciences, Spruce Biosciences, Neurocrine Bioscience, BridgeBio Pharma, Crinetics ...

Congenital adrenal hyperplasia (CAH) is characterized by imbalances in hormone production, including cortisol, aldosterone and androgens, which cause a wide range of symptoms and can lead to long ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies of CRENESSITY™ (crinecerfont). The data showed that a substantial ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented today a systematic literature review illustrating the relationship between higher glucocorticoid dose and adverse clinical outcomes, including ...

Patients with congenital adrenal hyperplasia (CAH) receiving glucocorticoid therapy showed reduced bone mineral density (BMD), with young adult male patients particularly affected and experiencing ...

Patients were excluded for conditions such as recent hospitalization, oral estrogen use, or congenital adrenal hyperplasia. The CST protocol involved administration of 250 µg of cosyntropin and ...

Crinetics Pharmaceuticals announced positive topline results from a Phase 2 study of atumelnant, a novel oral ACTH receptor antagonist, for treating congenital adrenal hyperplasia (CAH). The study ...

After seven decades with no advances in the treatment of the genetic disorder classic congenital adrenal hyperplasia (CAH), Neurocrine Biosciences has scored FDA approval for its first-in-class ...

Neurocrine Biosciences announced that the FDA has approved crinecerfont as an adjunct to glucocorticoid replacement to control androgens for patients with congenital adrenal hyperplasia ...

References: Neurocrine Biosciences announces FDA approval of Crenessity™ (crinecerfont), a first-in-class treatment for children and adults with classic congenital adrenal hyperplasia.

The primary driver of Fausto-Sterling’s exaggerated assessment was her inclusion of a condition known as late-onset congenital adrenal hyperplasia (CAH). The classic version of this condition occurs ...